A significant increase in the prevalence in age-related conditions such as visual impairment and blindness is anticipated due to the age-structure of the population worldwide. In line with the ageing population, the market for treatments of such age-related diseases is estimated to grow rapidly. This article focuses the market for age-related macular degeneration treatments and discusses products in development.